BioPharma Dive March 28, 2024
Jonathan Gardner

The regulator gave the drug an OK after receiving more safety data from Akebia, but imposed a strict boxed warning for its use.

Dive Brief:

  • The Food and Drug Administration has approved Akebia Therapeutics’ blood-boosting pill Vafseo for people with anemia from chronic kidney disease, the company said Wednesday, reversing a rejection the agency made two years ago over the drug’s safety.
  • The decision came after a review of safety data from Japan, where Vafseo has been used since 2020, in addition to clinical trials Akebia completed before its initial application. Last year, the regulator approved a similarly acting pill called Jesduvroq from GSK with extensive safety restrictions and warnings.
  • Vafseo can only be used in kidney disease patients...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
Related Articles:
FDA Approves First Biosimilar of Xolair
Opinion: STAT+: How will the Center for Biologics Evaluation and Research change under RFK Jr.?
How the FDA Opens the Door to Risky Chemicals in America’s Food Supply
FDA OKs First Gene Therapy Implant for a Rare Eye Disease
Gene Therapy in an Implant: Neurotech Lands First FDA Approval in Rare Vision Disorder

Share This Article